Bausch + Lomb Corporation
BLCOHealthcareNASDAQMedical Instruments & Supplies · Last scanned Oct 26, 2026
Scan Results
Daily timeframeBausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and. The $6.24B market capitalization puts BLCO squarely in mid-cap range for its industry. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical.
Market Cap
$6.24B
Beta
0.56
P/E (TTM)
—
P/E (Fwd)
15.69
EPS (TTM)
$-0.49
EPS (Fwd)
$1.11
ROE
-2.5%
ROA
1.8%
Cash
$367.0M
Total Debt
$5.11B
Free CF
$323.0M
52W Change
13.7%
Annual Financials
Cash vs Debt
Where BLCO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BLCO finished 1.22% above its 150-day moving average ($16.41) and 0.06% below its 200-day moving average ($16.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BLCO overbought or oversold?
At the October 20, 2026 close, BLCO's RSI(14) was 42.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Bausch + Lomb Corporation carries $5.11B in total debt against $367.0M in cash reserves — debt is roughly 13.9x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $323.0M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -2.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $3.77B (2022) to $5.10B (2025), reflecting a 35% increase over the period.
BLCO's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Bausch + Lomb Corporation carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Bausch + Lomb Corporation's trajectory.